TY - JOUR T1 - Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension JF - European Respiratory Journal JO - Eur Respir J SP - 1514 LP - 1516 DO - 10.1183/13993003.01004-2016 VL - 48 IS - 5 AU - Peter M. Hickey AU - Alfred A.R. Thompson AU - Athanasios Charalampopoulos AU - Charles A. Elliot AU - Neil Hamilton AU - David G. Kiely AU - Allan Lawrie AU - Ian Sabroe AU - Robin Condliffe Y1 - 2016/11/01 UR - http://erj.ersjournals.com/content/48/5/1514.abstract N2 - We read with interest the recent correspondence from Quilot et al. [1] describing a likely case of ponatinib-associated pulmonary arterial hypertension (PAH). The authors hypothesised that the mechanism by which tyrosine kinase inhibitors (TKIs) such as dasatinib and ponatinib, used for the treatment of chronic myeloid leukaemia (CML), induce PAH may involve their common inhibition of the non-receptor tyrosine kinase, Src [1]. Here, we present a patient who developed marked worsening of pre-existing TKI-associated PAH following commencement of bosutinib, a third-generation TKI also known to inhibit Src [2]. After marked improvement on withdrawal of bosutinib, the patient experienced further significant worsening of PAH after commencing ponatinib. We believe this is the first reported case linking bosutinib with PAH. It also supports the association between ponatinib and PAH and represents the first time that the development or worsening of PAH associated with multiple TKIs in the same patient has been reported.A patient with severe worsening of pre-existing PAH following treatment with bosutinib improved on cessation http://ow.ly/gJy7302uXL7 ER -